Portfolio

Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapyfor early-stage breast cancer

September 18, 2025

Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients, announces the publication of a landmark economic evaluation titled “Economic impact of MAF testing for adjuvant bisphosphonate therapy in early breast cancer: a multi-regional budget impact analysis from a payer perspective” (João L. Carapinha et al.), in the Journal of Medical Economics.

 

Read more